Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 4/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.40 |
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | GLI1 | P08151 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800667 | 1.00 | NOS2 (0.43) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL14443285 | 1.00 | NOS2 (0.43) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL26780565 | 0.94 | FDPS (0.38) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL420953 | 0.94 | FDPS (0.38) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL420946 | 0.94 | FDPS (0.38) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL23720635 | 0.89 | — | — | |
| SCHEMBL421836 | 0.89 | — | — | |
| SCHEMBL22436137 | 0.89 | — | — | |
| Trifluoroacetic Acid SCHEMBL5411611 | 0.88 | NOS2 (0.35) | NOS2NOS3NOS1PRCPDPP4 | |
| Trifluoroacetic Acid SCHEMBL5411607 | 0.88 | NOS2 (0.35) | NOS2NOS3NOS1PRCPDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858912-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858912-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230322743-A1 | NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES | MIHKAL GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230322743-A1 | NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES | MIHKAL GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230302430-A1 | SELENIOUS ACID ADSORBENT | NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY (JP) | 2023-09-28 | — | — | US | disclosed |
| US-20230234912-A1 | NOVEL ANALOGS OF PTEROSTILBENE AMINO ACID BEARING CARBONATES FOR TREATING A NON-ALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS | APICAL MOLECULAR BIOTECH CO., LTD. (TW) | 2023-07-27 | — | — | US | disclosed |
| EP-4197975-A1 | SELENIOUS ACID-ADSORBING MATERIAL | National University Corporation Kanazawa University (JP) | 2023-06-21 | — | — | EP | disclosed |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230124955-A1 | AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-04-20 | — | — | US | disclosed |
| US-20070254952-A1 | CANNABINOID RECEPTOR MODULATORS | SCHERING CORPORATION | 2007-11-01 | — | — | US | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-7238692-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-24 | — | — | US | disclosed |
| US-20070112043-A1 | Acylated and non-acylated imidazo[2,1-b]-1,3,4,-thiadiazole-2-sulfonamides, and uses thereof | AEGERA THERAPEUTICS, INC. (CA) | 2007-05-17 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| WO-2004071454-A2 | SUBSTITUTED AZETIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARMACEUTICALS INC. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858912-B2 | Heterocyclic compounds | F12, C1R, MRPL21 | NOS2 2375/4885NOS3 2454/4885NOS1 1832/4885 |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | NOS2 712/4885NOS3 513/4885NOS1 1098/4885 |
| US-20070112043-A1 | Acylated and non-acylated imidazo[2,1-b]-1,3,4,-thiadiazole-2-sulfonamides, and uses thereof | AADAC, NAT1, PMP22 | NOS2 3270/4885NOS3 2899/4885NOS1 3522/4885 |
| US-20070254952-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, GPR119 | NOS2 3262/4885NOS3 2772/4885NOS1 2850/4885 |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | TNNI3, IDH2, GLS | NOS2 191/4885NOS3 318/4885NOS1 477/4885 |
| US-20230322743-A1 | NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES | HTR2A, HTR2C, HTR1D | NOS2 1426/4885NOS3 2871/4885NOS1 2475/4885 |
| US-20230234912-A1 | NOVEL ANALOGS OF PTEROSTILBENE AMINO ACID BEARING CARBONATES FOR TREATING A NON-ALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS | FABP1, GLS2, SLC1A5 | NOS2 200/4885NOS3 438/4885NOS1 107/4885 |
| US-20070197628-A1 | Cannabinoid receptor modulators | CNR1, CNR2, GPR18 | NOS2 4213/4885NOS3 3549/4885NOS1 3426/4885 |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | F12, PM20D2, XDH | NOS2 2999/4885NOS3 2848/4885NOS1 2155/4885 |
| US-20230124955-A1 | AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | APLNR, NPPA, ARGLU1 | NOS2 893/4885NOS3 991/4885NOS1 1087/4885 |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | NOS2 712/4885NOS3 513/4885NOS1 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.